Published in

American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 2(57), p. 1040-1046, 2013

DOI: 10.1128/aac.01696-12

Links

Tools

Export citation

Search in Google Scholar

Anthelmintic Avermectins Kill Mycobacterium tuberculosis, Including Multidrug-Resistant Clinical Strains

Journal article published in 2012 by Leah E. Lim, Catherine Vilchèze, Carol Ng, William R. Jacobs, Santiago Ramón-García ORCID, Charles J. Thompson
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

ABSTRACT Avermectins are a family of macrolides known for their anthelmintic activities and traditionally believed to be inactive against all bacteria. Here we report that members of the family, ivermectin, selamectin, and moxidectin, are bactericidal against mycobacterial species, including multidrug-resistant and extensively drug-resistant clinical strains of Mycobacterium tuberculosis . Avermectins are approved for clinical and veterinary uses and have documented pharmacokinetic and safety profiles. We suggest that avermectins could be repurposed for tuberculosis treatment.